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Purpose: To evaluate the ability of the 8th edition of the American Joint Committee on Cancer (AJCC) Cancer
Staging Manual to estimate metastatic and mortality rates for children with retinoblastoma (RB).
Design: International, multicenter, registry-based retrospective case series.
Participants: A total of 2190 patients from 18 ophthalmic oncology centers from 13 countries over 6
continents.
Methods: Patient-specific data fields for RB were designed and selected by subcommittee. All patients with
RB with adequate records to allow tumor staging by the AJCC criteria and follow-up for metastatic disease were
studied.
Main Outcome Measures: Metastasis-related 5- and 10-year survival data after initial tumor staging were
estimated with the KaplaneMeier method depending on AJCC clinical (cTNM) and pathological (pTNM) tumor,
node, metastasis category and age, tumor laterality, and presence of heritable trait.
Results: Of 2190 patients, the records of 2085 patients (95.2%) with 2905 eyes were complete. The median
age at diagnosis was 17.0 months. A total of 1260 patients (65.4%) had unilateral RB. Among the 2085 patients,
tumor categories were cT1a in 55 (2.6%), cT1b in 168 (8.1%), cT2a in 197 (9.4%), cT2b in 812 (38.9%), cT3 in 835
(40.0%), and cT4 in 18 (0.9%). Of these, 1397 eyes in 1353 patients (48.1%) were treated with enucleation. A total
of 109 patients (5.2%) developed metastases and died. The median time (n ¼ 92) from diagnosis to metastasis
was 9.50 months. The 5-year KaplaneMeier cumulative survival estimates by clinical tumor categories were
100% for category cT1a, 98% (95% confidence interval [CI], 97e99) for cT1b and cT2a, 96% (95% CI, 95e97) for
cT2b, 89% (95% CI, 88e90) for cT3 tumors, and 45% (95% CI, 31e59) for cT4 tumors. Risk of metastasis
increased with increasing cT (and pT) category (P < 0.001). Cox proportional hazards regression analysis
confirmed a higher risk of metastasis in category cT3 (hazard rate [HR], 8.09; 95% CI, 2.55e25.70; P < 0.001) and
cT4 (HR, 48.55; 95% CI, 12.86e183.27; P < 0.001) compared with category cT1. Age, tumor laterality, and
presence of heritable traits did not influence the incidence of metastatic disease.
Conclusions: Multicenter, international, internet-based data sharing facilitated analysis of the 8th edition
AJCC RB Staging System for metastasis-related mortality and offered a proof of concept yielding quantitative,
predictive estimates per category in a large, real-life, heterogeneous patient population with RB. Ophthal-
mology 2020;127:1719-1732 ª 2020 by the American Academy of Ophthalmology. This is an open access article
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Ophthalmology Volume 127, Number 12, December 2020Retinoblastoma (RB) is one of the childhood cancers for
which survival of almost all affected children is possible.
However, timely diagnosis and prompt treatment must be
available.1 Disease-specific mortality has significantly
decreased over the past few decades.2 However, a
significant global disparity exists in regional mortality
rates, with rates in Asia and Africa as high as 40% to
70% compared with 3% to 5% in Europe, Canada, and
the United States.3-7 Delays in diagnosis, poor access to
eye cancer specialists, ophthalmic pathology, genetic
testing, and socioeconomic factors contribute to RB-related
loss of life.
In addition, the lack of a universally accepted classifi-
cation system prevents accurate medical communication
among eye cancer specialists, pediatric oncologists, radia-
tion therapists, ophthalmic pathologists, and research
workers. The impact of collaboration among international
research groups using a uniform staging system was
exemplified by the Children’s Oncology Group study of
rhabdomyosarcoma, in which cooperative research and
pooled analyses both increased knowledge about the disease
and improved cure rates.8,9
Classification systems for RB have evolved from changes
in treatment options.10-12 For example, the earliest, the
Reese-Ellsworth staging system, predicted globe salvage
after external beam radiation therapy.13 Then, with the
advent of systemic chemotherapy and adjuvant eye and
vision conserving therapies, newer classification systems
were introduced. These included the International
Intraocular Retinoblastoma Classification (IIRC) or
Children’s Hospital of Los Angeles (CHLA) classification
and the International Classification for Retinoblastoma
(ICRB), also known as the “Wills Eye Hospital” (WEH)
classification.10,11 Each of these last 2 classification
systems originated from a single institution and lack
published multicenter validation. These classifications
have been widely used to predict globe salvage from
chemotherapy-based treatments, not to predict prognosis
for life. In addition, significant differences exist, despite
many shared features. The lack of uniformity in worldwide
RB eye classification has been a hindrance for both research
and clinical care.14,15 In addition, the International
Retinoblastoma Staging System (IRSS) was developed for
extraocular disease.12 To date, not one of these systems
has been validated using large international multicenter
cohorts nor are they universally accepted.
To gain both international consensus and thus wide-
spread acceptance, writing of the 8th edition American Joint
Committee on Cancer (AJCC) RB staging system involved
18 RB specialist centers from 13 countries on 6 conti-
nents.16 The resultant AJCC cancer staging system not only
brings RB care into the mainstream of ophthalmic and
pediatric oncology but also provides a standardized
primary tumor (T), regional lymph node (N), systemic
metastasis (M) framework for RB communication
worldwide. The AJCC system has been adopted by the
Union for International Cancer Control and is thus
accepted by medical oncology, radiation oncology, and
medical journals around the world.17-201720The AJCC staging systems serve to standardize data
reporting, case-to-case prognostication, and selection of the
most suitable treatments.16 In addition, the AJCC RB
staging system not only provides TNM information but
also uniquely adds a new AJCC category heritable trait
(H). Based on medical evidence and thus accepted by the
AJCC, the H designation includes the presence of a germ-
line mutation as a risk factor for cancer-related mortality.
The AJCC Cancer Staging Manual, 8th edition staging for
RB serves as a complete intraocular, extraocular, and sys-
temic disease classification system that simplifies outcome
reporting. In contrast to the prior classification systems, it
was constructed to predict metastatic risk and patient sur-
vival. We present a foundational multicenter, international
study to evaluate the potential of the 8th edition of the AJCC
Cancer Staging System to predict metastasis-related mor-
tality based on tumor category. In addition, we compared
AJCC RB staging with prior existing RB classifications for
metastatic risk and patient survival. Comparisons for local
treatment efficacy and globe salvage can be found in Part II
of this series.
Methods
Patients were diagnosed with RB from January 5, 2001, to
December 31, 2013. Data were collected and entered into a secure
online database. This study adhered to the tenets of the Declaration
of Helsinki and the Health Insurance Portability and Accountability
Act of 1996.
All participating centers obtained internal institutional review
board approval to perform retrospective medical record reviews and
contribute de-identified data to the AJCC Ophthalmic Oncology
Task Force Retinoblastoma Registry. The Princess Margaret Cancer
Center determined, and all centers agreed that individual patient
consent was not required because there were no patient identifiers
collected in this retrospective study. Each participating site was an
ophthalmic oncology subspecialty center, and the patients were
diagnosed and treated as per the best practices defined by each
institute. Patient records were excluded from analysis if key vari-
ables, such as demographic data, presenting clinical variables,
treatment data, and outcome, were missing or inconsistent.
The Registry
An internet-based, retrospective registry was created to evaluate the
staging system for RB in the 8th edition of the AJCC Cancer
Staging Manual.16 Through a consensus process, retinoblastoma
AJCC Ophthalmic Oncology Task Force committee members
(primarily ophthalmic oncologists and pathologists) developed
epidemiological, clinical, and pathological data fields. The scope
of the present study was limited to the evaluation of 8th edition
AJCC TNMH staging with regard to the risk of metastasis and
RB-related mortality.
Internet Database and Security
Secure data storage met international standards for patient privacy
protection and statistical analysis. Security measures included the
lack of personal patient identifiers, Secure Sockets Layer encryp-
tion, protection against Structured Query Language injection,
variable and session management, record locking, and trail auditing
(e.g., failed login attempts and webpage accessing). In addition,
access to the online survey required user accounts issued by the
Table 1. The American Joint Committee on Cancer 8th Edition TNM Classification for Retinoblastoma16
Definitions for Primary Tumor Staging (cT)
cTX Unknown evidence of intraocular tumor
cT0 No evidence of intraocular tumor
cT1 Intraocular tumor(s) with subretinal fluid 5 mm from the base of any tumor
cT1a Tumors 3 mm and farther than 1.5 mm from the disc and fovea
cT1b Tumors >3 mm or closer than 1.5 mm to the disc and fovea
cT2 Intraocular tumor(s) with retinal detachment, vitreous seeding, or subretinal seeding
cT2a Subretinal fluid >5 mm from the base of any tumor
cT2b Tumors with vitreous seeding or subretinal seeding
cT3 Advanced intraocular tumor(s)
cT3a Phthisis or pre-phthisis bulbi
cT3b Tumor invasion of the pars plana, ciliary body, lens, zonules, iris, or anterior chamber
cT3c Raised intraocular pressure with neovascularization or buphthalmos
cT3d Hyphema or massive vitreous hemorrhage
cT3e Aseptic orbital cellulitis
cT4 Extraocular tumor(s) involving the orbit, including the optic nerve
cT4a Radiologic evidence of retrobulbar optic nerve involvement or thickening of the optic nerve or
involvement of the orbital tissues
cT4b Extraocular tumor clinically evident with proptosis and orbital mass
Definitions for Regional Lymph Node Staging (cN)
cNX Regional lymph nodes cannot be assessed
cN0 No regional lymph node involvement
cN1 Evidence of preauricular, submandibular, and cervical lymph node involvement
Definitions for Distant Metastasis Staging (M)
cM0 No signs or symptoms of intracranial or distant metastasis
cM1 Distant metastasis without microscopic confirmation
cM1a Tumor(s) involving any distant site (e.g., bone marrow, liver) on clinical or radiologic tests
cM1b Tumor involving the CNS on radiologic imaging (not including trilateral RB)
pM1 Distant metastasis with microscopic confirmation
pM1a Histopathologic confirmation of tumor at any distant site (e.g., bone marrow, liver, or other)
pM1b Histopathologic confirmation of tumor in the cerebrospinal fluid or CNS parenchyma
Definitions for Heritable Trait Staging (H)
HX Unknown or insufficient evidence of a constitutional RB1 gene mutation
H0 Normal RB1 alleles in blood tested with demonstrated high sensitivity assays
H1 Bilateral RB, RB with an intracranial CNS midline embryonic tumor (i.e., trilateral RB), patient with
family history of RB, or molecular definition of constitutional RB1 gene mutation
Definitions for Pathological Tumor Staging (pT)
pTX Unknown evidence of intraocular tumor
pT0 No evidence of intraocular tumor
pT1 Intraocular tumor(s) without any local invasion, focal choroidal invasion, or pre- or intralaminar
involvement of the optic nerve head
pT2 Intraocular tumor(s) with local invasion
pT2a Concomitant focal choroidal invasion and pre- or intralaminar involvement of the optic nerve head
pT2b Tumor invasion of stroma of iris or trabecular meshwork or Schlemm’s canal
pT3 Intraocular tumor(s) with significant local invasion
pT3a Massive choroidal invasion (>3 mm in largest diameter, or multiple foci of focal choroidal involvement
totaling >3 mm, or any full-thickness choroidal involvement)
pT3b Retrolaminar invasion of the optic nerve head, not involving the transected end of the optic nerve
pT3c Any partial-thickness involvement of the sclera within the inner two-thirds
pT3d Full-thickness invasion into the outer third of the sclera or invasion into or around emissary channels
pT4 Evidence of extraocular tumor: tumor at the transected end of the optic nerve, tumor in the meningeal
spaces around the optic nerve, full-thickness invasion of the sclera with invasion of the episclera,
adjacent adipose tissue, extraocular muscle, bone, conjunctiva, or eyelids
CNS ¼ central nervous system; RB ¼ retinoblastoma.
Tomar et al  AJCC Staging of Retinoblastomacoordinating center. Each center could only access records perti-
nent to their site. When documentation of approval from the local
ethics committee was received by the coordinating center, uniquelogin passwords were provided to initiate patient entry. All data
were deidentified at the local center, where a random study iden-
tifier was generated for each patient.1721
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Each center used its own diagnostic and therapeutic methods. Data
collected included date of diagnosis, age at diagnosis (months),
hereditary pattern (familial, sporadic), laterality (unilateral, bilat-
eral), and the eye involved (right, left). The clinical information
included intraocular pressure, presence of macroscopic anterior
chamber seeding, and neovascularization of the iris. Reese-
Ellsworth, CHLA (IIRC), WEH (ICRB), IRSS, and TNMH
staging of RB were noted for each eye. The terms “CHLA” and
“WEH” were preferred in this study instead of IIRC and ICRB,
respectively, to prevent any ambiguity in these 2 similar-sounding
but distinct classification systems and to avoid confusion for the
readers. For bilateral RB (by AJCC convention), the worse eye
tumor category was attributed to the overall clinical (cT) and
pathological (pT) category for survival analysis. A similar
approach was used for CHLA and WEH, where the worse eye
group (A to E) was attributed to the patient for survival analysis.
This analysis was performed for comparative statistical analysis
and does not suggest use of these prior classifications when
predicting patient survival.
Treatment details were noted. Information regarding the
outcome included the occurrence of metastasis, date of detection of
metastasis, and site of metastasis. The final patient outcome (alive
without metastasis, alive with metastasis, alive with second
malignant neoplasm, dead with metastasis, dead with second
malignant neoplasm, dead because of other causes, or lost to
follow-up), the date of the last follow-up, and the duration of
follow-up were noted. All patients with central nervous system
metastasis who were lost to follow-up were considered deceased
and included in the metastasis-related mortality analysis. The pa-
tients whose treatment was discontinued by request of their
guardians and were lost to follow-up and eventually were noted to
have died of the disease were also included in metastasis-related
mortality. All other non-metastasis-related deaths were noted but
censored from the analysis.
TNMH Retinoblastoma Staging
The primary tumor extent, node, metastasis, and heritable trait, as
well as the anatomic and prognostic groups, were defined in
accordance with the 8th edition of the AJCC Cancer Staging
Manual on RB (Table 1).16 The registry data fields and collection
predated AJCC 8th edition. Thus, we used the raw clinical data toFigure 1. Cumulative frequency plot for age at presentation for 2085 patients
1722classify all the cases accurately by AJCC 8th edition. Data were
available for all necessary fields except the following: (1)
involvement of pars plana and ciliary body (cT3b); (2)
distinction between cT4 subcategories (radiologic vs. overt
orbital involvement); and (3) data regarding pT2b (anterior
segment involvement) were not recorded.
Statistical Analysis
Continuous variables were described using medians, ranges, and
interquartile ranges (IQRs), and categoric variables were described
using frequencies and proportions. Log-rank tests for trend,
KaplaneMeier plots, and Cox proportional hazards regression
models were implemented to test for evidence suggesting that
tumor category is related to metastasis. Cumulative proportions of
surviving patient estimates at 1, 5, and 10 years were tabulated.
SPSS Version 23.0 (SPSS Inc., Chicago, IL) was used to generate
KaplaneMeier plots and to perform all other statistical analyses.
Statistical significance was set at P < 0.05, and no adjustments
were made for multiple tests.Results
In this study, 2190 patients were enrolled between January 2001
and December 2013. Eighteen eye cancer specialty centers from 13
countries in more than 6 continents successfully entered data online
into our internet-based registry. A total of 105 patients were
excluded because of incomplete data. Thus, complete records
for analysis were available for 2085 patients (95.2%) and 2905 RB-
affected eyes.
Patient Features
The median age at diagnosis was 17.0 months (mean, 21.6;
standard deviation [SD], 20.9; IQR, 8e29; range, 1e365
months). Of the 1928 patients, 1260 (65.4%) had unilateral RB
and 668 (35.6%) had bilateral RB. Among the patients with
unilateral RB, the right eye was involved in 734 (51.9%). As
expected, the patients with unilateral RB were older at presen-
tation than the bilateral RB. The number of patients who pre-
sented at an age of less than 12 months was 826 (39.6%), less
than 36 months was 1770 (84.9%), and more than 8 years was 18
(0.80%) (Fig 1). A genetic test for RB1 pathogenic variant waswith retinoblastoma.
Table 2. Classification of Eyes and Patients Based on Different Retinoblastoma Classification Systems
Reese-Ellsworth Classification (N [ 1262 eyes)13 Number % of Total
Data not available 1462
Group Ia: <4 disk diameters behind equator; solitary tumor 102 8.1%
Group Ib: <4 disk diameters behind equator; multiple tumor 66 5.3%
Group IIa: 4e10 disk diameters behind equator; solitary tumor 61 4.9%
Group IIb: 4e10 disk diameters behind equator; multiple tumor 58 4.6%
Group IIIa: any tumor anterior to equator 89 7.0%
Group IIIb: solitary tumor >10 disk diameters behind equator 37 2.9%
Group IVa: multiple tumors, some more >10 disk diameters 48 3.8%
Group IVb: any tumor anterior to ora serrata 43 3.4%
Group Va: massive tumors seeding more than half the retina 312 24.7%
Group Vb: vitreous seeding 446 35.3%
International Intraocular Retinoblastoma Classification (Children’s Hospital of Los Angeles) (N [ 2866 eyes)11
Data not available 19
Group A 176 6.1%
Group B 476 16.5%
Group C 212 7.3%
Group D 1119 38.8%
Group E 903 31.3%
International Classification of Retinoblastoma (Wills Eye Hospital) (N [ 2866 eyes)10
Data not available 19
Group A 188 6.5%
Group B 602 20.8%
Group C 40 1.4%
Group D 281 9.7%
Group E 1775 61.6%
International Retinoblastoma Staging System (N [ 958 patients)12
Data not available 1127
0, Patient treated conservatively 287 30.0%
I, Eye enucleated; tumor completely resected 605 63.2%
II, Eye enucleated; microscopic residual tumor 35 3.7%
IIIa, Overt orbital disease 11 1.1%
IIIb, Preauricular or cervical node tumor 2 0.2%
IVa1, Hematogenous metastasis without CNS disease, single lesion 2 0.2%
IVa2, Hematogenous metastasis without CNS disease, multiple lesion 3 0.3%
IVb1, CNS disease ( other metastasis); prechiasmal 3 0.3%
IVb2, CNS disease ( other metastasis); CNS mass 2 0.2%
IVb3, CNS disease ( other metastasis); leptomeningeal and CSF 8 0.8%
CNS ¼ central nervous system; CSF ¼ cerebrospinal fluid.
Tomar et al  AJCC Staging of Retinoblastomaperformed on 44 patients (2.1%), and 14 (31%) of them were
found positive.
Classifications
The proportions of the same registry eyes staged by the
different classifications/staging schema illustrate the
different features of the 5 schemas. The Reese-Ellsworth
classification13 was reported in 1262 eyes as follows: A
total of 168 eyes were in group I (13.3%); 119 eyes were
in group II (9.4%); 126 eyes were in group III (10.0%);
91 eyes were in group IV (7.3%); 758 eyes were in group
V (60.0%). Data were not available for 1643 eyes (Table 2).
The CHLA (IIRC)11 was reported in 2886 eyes as
follows: A total of 176 eyes were in group A (6.1%); 476
eyes were in group B (16.5%); 212 eyes were in group C(7.3%); 1119 eyes were in group D (38.8%); 903 eyes
were in group E (31.3%). Data were not available for 19
eyes (Table 2).
The WEH (ICRB)10 was reported in 2886 eyes as
follows: A total of 188 eyes were in group A (6.5%); 602
eyes were in group B (20.8%); 40 eyes were in group C
(1.4%); 281 eyes were in group D (9.7%); 1775 eyes were
in group E (61.6%). Data were not available for 19 eyes
(Table 2).
The IRSS12 was reported in 958 patients as follows: A
total of 287 had stage 0 (30.0%); 605 had stage 1
(63.2%); 35 had stage 2 (3.7%); 11 had stage 3A (1.1%);
2 had stage 3B (0.2%); 2 had stage 4A1 (0.2%); 3 had
stage 4A2 (0.3%); 3 had stage 4B1 (0.3%); 2 had stage
4B2 (0.2%); 11 had stage 4B3 (0.8%). Data were
unavailable for 1127 patients (Table 2).1723
Table 3. Classification of Eyes and Patients per American Joint
Committee on Cancer 8th Edition TNM Classification for
Retinoblastoma16
Primary Tumor (cT)
N ¼ 2905 eyes N %
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N ¼ 2085 patients N %
H0 1329 63.7%
H1 756 36.3%
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Classification
Compared with the aforementioned classification systems,
the 8th edition AJCC Classification includes more complex
information about the patients’ primary tumor, regional
lymph node spread, metastatic disease, and heredity.16
These are described next.American Joint Committee on Cancer Clinical
Classification
The eye-level clinical tumor category (cT) in 2905 eyes was
as follows: cT1 in 698 (24.0%); cT2 in 1355 (46.6%); cT3
in 830 (28.6%); cT4 in 22 (0.8%). The patient-level clinical
tumor category (cT) for 2085 patients were as follows: cT1a
in 55 (2.6%); cT1b in 168 (8.1%); cT2a in 197 (9.4%); cT2b
in 812 (38.9%); cT3 in 835 (40.0%); cT4 in 18 (0.9%)
(Table 3).American Joint Committee on Cancer
Pathological Classification
Of the 2905 eyes, 1397 eyes (48.1%) of 1353 patients were
treated with enucleation. Of these, 44 patients had bilateral
enucleation (0.1%). The patient-level pathological tumor
category (pT) in 1353 patients was as follows: pT1 in 491
(36.3%); pT2 in 466 (34.4%); pT3 in 323 (23.9%); pT4 in
73 (5.4%) (Table 3).American Joint Committee on Cancer Nodes,
Metastasis, and Heritable Trait
According to the regional lymph node involvement classi-
fication (cN), 12 patients (0.6%) were reported as cN1. The
lymph nodes involved were preauricular, cervical, or sub-
mandibular. According to the distant metastasis classifica-
tion (cM) of the 2085 patients, 13 were cM1a (0.6%),
including 3 patients with distant lymph nodes and 12
patients with central nervous system metastasis and thus
cM1b (0.6%) at presentation.
According to the AJCC rules, we classified heritable trait
(H) by considering bilateral disease, family history of RB,
presence of pinealoblastoma, and presence of pathogenic
RB variant on genetic testing. Thus, of the 2085 patients,
heritable trait was seen in 756 (36.3%) (Table 3).
An additional 84 patients developed metastasis over the
median follow-up period of 48.0 months (mean, 53.80; SD,
41.50; IQR, 20e79 months). The median time to metastasis
in 92 patients was 9.5 months (mean, 13.7; SD, 13.6; IQR,
4e19.8 months). The different sites to metastasis were
distant lymph nodes, bone, bone marrow, and central ner-
vous system (including cerebrospinal fluid, leptomeninges,
pre- and postchiasmatic central nervous system sites).
Multiorgan metastasis was seen in 34 of 109 patients
(31.2%).
Table 4. Kaplan-Meier Cumulative Proportion of Surviving Patients for AJCC Clinical T Category, CHLA, and WEH Classification for
2085 Patients with Retinoblastoma
Classification Variable
KaplaneMeier Point Estimates (95% CI), %
1 Yr 5 Yrs 10 Yrs
All patients (n ¼ 2085) 95 (94e96) 95 (94e96) 93 (92e94)
CHLA Classification (n ¼ 2085) A (n ¼ 27) 100 100 100
B (n ¼ 178) 100 98 (97e99) 97 (95e99)
C (n ¼ 112) 99 (98e100) 99 (98e100) 99 (98e100)
D (n ¼ 904) 98 97 (96e98) 97 (96e98)
E (n ¼ 864) 90 (89e91) 88 (87e89) 88 (87e89)
WEH Classification (n ¼ 2080) A (n ¼ 29) 100 100 100
B (n ¼ 240) 100 100 99 (98e100)
C (n ¼ 26) 100 100 100
D (n ¼ 195) 100 100 100
E (n ¼ 1590) 94 (93e95) 91(90e92) 91 (90e92)
AJCC cT size category (n ¼ 2085) cT1a (n ¼ 55) 100 100 100
cT1b (n ¼ 168) 100 98 (97e99) 96 (94e98)
cT2a (n ¼ 197) 99 (98e100) 98 (97e99) 98 (97e99)
cT2b (n ¼ 812) 98 (97e99) 96 (95e97) 96 (95e97)
cT3 (n ¼ 835) 91 (90e92) 89 (88e90) 89 (88e90)
cT4 (n ¼ 18) 63 (51e75) 45 (31e59) Not available
For CHLA classification.
Overall comparison: Wilcoxon P < 0.001.




D 0.400 0.228 0.312
E 0.064 <0.001 ¼0.001 <0.001
For WEH classification
Overall comparison: Wilcoxon P < 0.001




D N/A 0.317 N/A
E 0.117 <0.001 0.126 <0.001
For cT category
Overall comparison: Wilcoxon P < 0.001




cT2b 0.198 0.182 0.250
cT3 0.011 <0.001 <0.001 <0.001
cT4 <0.001 <0.001 <0.001 <0.001 <0.001
KaplaneMeier Cumulative Proportion of Surviving Patients for AJCC Pathological T Category for 1353 Patients with Retinoblastoma
KaplaneMeier Point Estimates, % (95% CI)
Variable 1 Yr 5 Yrs 10 Yrs
All patients (N ¼ 1353) 96 (95e97) 94 (95e96) 94 (93e95)
pT1 (N ¼ 491) 99 99 98 (97e99)
pT2 (N ¼ 466) 99 98 (97e99) 98 (97e99)
pT3 (N ¼ 323) 94 (93e95) 91 (89e93) 91 (89e93)
(Continued)
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Table 4. (Continued.)
KaplaneMeier Point Estimates, % (95% CI)
Variable 1 Yr 5 Yrs 10 Yrs
pT4 (N ¼ 73) 61 (55e67) 48 (41e55) 48 (41e55)
Overall comparison: P < 0.001
Pairwise comparison (P value) pT3a pT3b pT3c
pT3a
pT3b P ¼ 0.109
pT3c P ¼ 0.403 P ¼ 0.645
pT3d P < 0.001 P ¼ 0.004 P ¼ 0.008
AJCC ¼ American Joint Committee on Cancer 8th edition; CHLA ¼ Children’s Hospital of Los Angeles; CI ¼ confidence interval; N/A ¼ not available;
WEH ¼ Wills Eye Hospital.
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Twenty-one patients with RB (1.0%, 19 patients with
bilateral and 2 patients with unilateral) were noted to have
multiple cancers at diagnosis or during follow-up. The
tumors were pineal (trilateral RB) tumor in 15 patients
(0.8%, 71% of other cancers) and olfactory neuroblastoma,
acute myeloid leukemia, acute lymphoid leukemia, osteo-
sarcoma, rhabdomyosarcoma, and palate and maxillary si-
nus sarcoma in 1 patient each.Figure 2. KaplaneMeier curves of cumulative survival estimates for 2085 pati
Tumor (cT) category for retinoblastoma.
1726Cumulative Proportion Estimates of Survival
According to Initial cTNM
Of the 2085 patients, 109 (5.2%) developed metastatic
disease and eventually died of the disease. The median time
from presentation to development of metastasis in
92 patients was 9.50 months (mean, 13.7; SD, 13.6, IQR,
4.0e19.8). According to the AJCC criteria, of the 109
patients who developed metastasis, 3 (2.7%) were cT1b, 3
(2.7%) were cT2a, 22 (20.2%) were cT2b, 73 (67.0%) wereents, classified by American Joint Committee on Cancer (AJCC) Clinical
Figure 3. KaplaneMeier curves of cumulative survival estimates for 2085 patients, classified by Children Hospital Los Angeles (CHLA) classification for
retinoblastoma.
Tomar et al  AJCC Staging of RetinoblastomacT3, and 8 (7.3%) were cT4. The 5-year KaplaneMeier
cumulative survival estimates by clinical tumor categories
were 100% for category cT1a, 98% (95% confidence in-
terval [CI], 97e99) for cT1b and cT2a, 96% (95% CI,
95e97) for cT2b, 89% (95% CI, 88e90) for cT3, and 45%
(95% CI, 31e59) for cT4. Increasing tumor category
translated to increased risk of metastasis-related mortality
and decreased survival (P < 0.001, log-rank test for trend).
Pairwise comparison showed a significant difference
between all categories except between cT1 and cT2 (Table 4
and Figs 2e4).
Cumulative Proportion Estimates of Survival
According to Initial pTNM
Of the 1353 patients who underwent enucleation, 69 (5.1%)
developed metastatic disease and eventually died of the
disease. According to the AJCC criteria, of the 69 patients
who developed metastasis, 4 (5.8%) had pT1, 9 (13%)
had pT2, 24 (34.8%) had pT3, and 32 (46.4%) had pT4. The
5- and 10-year KaplaneMeier cumulative survival estimatesby tumor categories were 99% and 98% (95% CI, 97e99)
for pT1 tumors, 98% (95% CI, 97e99) (both 5 and 10
years) for pT2 tumors, 91% (95% CI, 89e93; both 5 and 10
years) for pT3 tumors, and 48% (95% CI, 41e55; both 5
and 10 years) for pT4 tumors, respectively. Increasing tumor
category was consistent with increased risk of metastasis-
related mortality and decreased survival (P < 0.001), log-
rank test for trend (Table 4 and Fig 5).Cox Proportional Hazards Regression Analysis
In this study, age (hazard ratio [HR], 1.09; 95% CI,
1.01e1.16; P ¼ 0.016), tumor laterality (HR, 1.09; 95% CI,
0.74e1.61; P ¼ 0.661), and presence of heritable trait (HR,
1.06; 95% CI, 0.72e1.57; P ¼ 0.750) did not influence the
incidence of metastatic disease on Cox proportional hazard
regression analysis. Patients with cT3 (HR, 8.09; 95% CI,
2.55e25.70; P < 0.001) and cT4 categories (HR, 48.55;
95% CI, 12.86e183.27; P < 0.001) had greater risk of
metastasis compared with those with cT1 (Table 5).1727
Figure 4. KaplaneMeier curves of cumulative survival estimates for 2085 patients, classified by Wills Eye Hospital (WEH) classification for retinoblastoma.
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3.38e28.13; P < 0.001) and pT4 categories (HR, 77.26;
95% CI, 27.28e218.77; P < 0.001) had significantly
higher risk of metastasis compared with those with pT1
(Table 5).Discussion
This study included patients from many of the largest
international RB subspecialty centers and smaller national
and regional referral RB centers. Their participation allowed
for inclusion of worldwide data and thus an unusually
diverse sampling of patients. These numbers were large
enough to obtain statistically significant results. We used the
multicenter, international, internet-based registry to retro-
spectively validate the 8th edition of the AJCC Cancer
Staging Manual system for RB. That is, we confirm that1728increasing AJCC cT and pT categories were significantly
related to increased risk of metastasis-related mortality.
Specifically, as the tumor category increased from cT1 to
cT4, the odds of metastasis increased exponentially. This
study revealed an 8.09-fold risk for cT3 and a greater than
48.55-fold risk for cT4 compared with cT1. As found in
enucleated eyes, the presence of the high-risk features
categorized as pT3 or pT4 was associated with higher risks
of metastasis and should prompt metastasis screening.
Classification for a disease is necessary for appropriate
management strategies and predicting prognosis. But the use
of multiple classification systems has led to confusion and
miscommunication that undermine RB research and patient
care.15 For example, the Reese-Ellsworth classification,
introduced to stage the results of external beam radiation
therapy, became rarely used as that modality waned. Like-
wise, the CHLA and WEH classifications were primarily
introduced to predict globe salvage after systemic
Figure 5. KaplaneMeier curves of cumulative survival estimates for 1353 patients, classified by American Joint Committee on Cancer (AJCC) pathological
tumor (pT) category for retinoblastoma.
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prognosis. Both had the same “A” to “E” classification
scheme with subtle but significant criteria differences,
leading to non-comparable results.10,11
Although helpful for treatment-specific outcome predic-
tion, these classification systems were developed by single
centers and largely based on a single author’s experience or
small group consensus. They have not been validated by
published large multicenter studies. The disparity between
them is elucidated in our results in which the same cohort
had 31.3% eyes classified in group E as per CHLA classi-
fication and 61.6% as per WEH classification (Table 2).
When comparing these with the TNM classification, cT3
resembles most closely group E and includes 39.9% of all
eyes. Unfortunately, the majority of studies stratifying
globe salvage rates by WEH or CHLA classification fail
to specify which version was used.15
To focus on patients with RB with extraocular extension,
the IRSS emphasizes the presence and risk of extraocular
relapse.12 In contrast, the AJCC TNMH classification
encompasses the whole spectrum of RB disease and is
thus multifunctional. To include these aspects, the lead
authors of the IRSS were invited to participate in writing
the 8th edition AJCC RB staging system.
The regional epidemiology of RB has been discussed in
multiple studies.21-23 However, ours is the first multicenterstudy, with patients from all 6 continents who have been
uniformly classified within a single classification system,
that provides an assessment of the risk of metastasis and
loss of life. The finding that the cumulative survival pro-
portion with respect to tumor categories showed a steep
decline from cT1a (100%) to cT4 (45%) and from pT1
(99%) to pT4 (48%) at the 5-year follow-up supports the
validity of the 8th edition AJCC staging system. When
compared with CHLA and WEH, the AJCC TNMH clas-
sification shows a better tumor stratification in terms of
risk for metastasis-related mortality. Therefore, this study
shows that AJCC-TNMH is superior for predicting RB
metastasis and thus provides evidence that clinical and
research groups should switch from CHLA and WEH to
AJCC staging.
In this study, we show that a drastic increase in the risk of
metastasis was associated with increased tumor volume and
presence of extraocular disease. For example, in an eye
treated with enucleation, risk of metastatic RB is maximum
with pT3d (50-fold) and pT4 (77-fold) compared with an
intraocular tumor without any local invasion (pT1). Clearly,
prognosis of patients with RB worsens drastically once RB
breaches the ocular coats.24 Other risk factors hypothesized
for increasing the metastatic risk include lower age at
diagnosis, tumor laterality, presence of heritable trait, and
trilateral RB.24,25 In contrast, Cox proportional hazards1729
Table 5. Cox Proportional Hazard Regression Models
Cox Proportional Hazards Regression Model for Association of Age, Tumor Laterality, and H Category with Metastatic Mortality
Variable
Patients in Category, No. (%)
(N ¼2085) Reference HR (95% CI) P Value
Age 2085 (100.0%) 1-yr increment 1.09 (1.01e1.16) 0.016
Bilateral 748 (35.9%) Unilateral 1.09 (0.74e1.61) 0.661
H1 756 (36.3%) H0 1.06 (0.72e1.57) 0.750
Cox Proportional Hazards Regression Model for Association of AJCC Clinical T (cT) Category with Metastatic Mortality
Variable
Patients in Category, No. (%)
(N ¼2085) Reference HR (95% CI) P Value
cT2 1010 (48.4%) cT1 2.05 (0.62e6.80) 0.24
cT3 831 (39.9%) cT1 8.09 (2.55e25.70) <0.001
cT4 18 (0.9%) cT1 48.55 (12.86e183.27) <0.001
Cox Proportional Hazards Regression Model for Association of AJCC Pathological T (pT) Category with Metastatic Mortality
Variable
Patients in Category, No. (%)
(N ¼1353) Reference HR (95% CI) P Value
pT2 466 (34.4%) pT1 2.42 (0.75e7.87) 0.140
pT3 323 (23.9%) pT1 9.76 (3.38e28.13) <0.001
pT4 73 (5.4%) pT1 77.26 (27.28e218.77) <0.001
Cox Proportional Hazards Regression Model for Association of AJCC Pathological T3 Subcategory (pT) Category with Metastatic Mortality
Variable Patients in Category, No. (%) (N ¼1353) Reference HR (95% CI) P Value
pT3a 106 (7.8%) pT1 4.89 (1.22e19.56) 0.020
pT3b 156 (11.5%) pT1 10.90 (3.55e33.44) <0.001
pT3c 50 (3.7%) pT1 8.12 (1.82e36.28) 0.006
pT3d 11 (0.8%) pT1 49.74 (12.44e198.9) <0.001
AJCC ¼ American Joint Committee on Cancer 8th edition; CI ¼ confidence interval; HR ¼ hazard ratio.
Ophthalmology Volume 127, Number 12, December 2020regression analysis showed that younger age, laterality, and
presence of heritable traits do not significantly influence the
risk of metastasis.
Limitations of our study are based on the inherent na-
ture of data entry from 2001 to 2013 (before the 8th edi-
tion TNMH RB staging). The retrospective design of the
study is also a limitation. Although we did not ask for data
regarding patient sex and ethnic/racial backgrounds, the
data were collected from 6 continents and thus sourced
from a diverse group of patients. The data fields did not
include the pars plana and ciliary body involvement,
which may have resulted in the depreciation of the cT3b
subcategory. Another limitation was that cT4a and cT4b
were not differentiated, which prevented that specific
analysis for those TNM prognostic stage groups.
Furthermore, genetic testing was performed on a small
cohort of patients. This likely reflected the timing of data
collection and the local availability of genetic services.
Therefore, our H-status data may not accurately represent
the presence of heritable traits in patients with unilateral
RB. This bias could have led to an underestimation of its
significance with respect to metastatic disease. The data
regarding pT2b (anterior segment involvement) were not
recorded, preventing analysis of anterior segment
involvement as a risk factor for metastatic disease. The1730data fields for IRSS data were incomplete for 1127 patients
(54%); therefore, a meaningful comparison between AJCC
and IRSS could not be performed. In that trilateral RB is
classified separately in the AJCC system, it was not
specifically registered in our study. Although mentioned as
additional information in some reports, some of the
trilateral tumors could have developed during later
follow-up.
In review of the literature, a meta-analysis has sug-
gested that the incidence of trilateral RB is 3.8% (among
patients with bilateral RB).26 Applied to our study, this
would translate to approximately 25 patients. However,
in our study, there were 668 bilaterally affected
patients, and only 15 (2.2%) were found to have
trilateral disease.
In conclusion, the 8th edition AJCC classification for
RB was derived from evidence-based data and interna-
tional consensus. This retrospective data analysis provided
significant evidence that AJCC-RB staging can be used for
predicting metastasis-associated mortality. However, a
future independent prospective study could provide a more
powerful independent validation of the AJCC-TNMH
staging system. We believe that the universal adoption
of this classification system will clarify outcome reporting
and improve research and patient care. We show that
Tomar et al  AJCC Staging of Retinoblastomainternational, multicenter, registry-based studies of rare
cancers can be performed using internet-based data
sharing. The 8th edition AJCC classification for RB was
used to accurately estimate mortality related to metastatic
disease.
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